Volume 19, Issue 2 (March - April 2020)
Payesh 2020, 19(2): 139-144 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Pezeshki M Z, Shojaeefar E. The necessity of urgent low-cost epidemiological studies with short duration about the role of BCG vaccine in preventing and controlling of COVID-19 in Iran. Payesh 2020; 19 (2) :139-144
URL: http://payeshjournal.ir/article-1-1339-en.html
URL: http://payeshjournal.ir/article-1-1339-en.html
1- Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2- Member of Immunology Board For Transplantation And Cell-Based therapeutics at USERN, Tehran, Iran
2- Member of Immunology Board For Transplantation And Cell-Based therapeutics at USERN, Tehran, Iran
Abstract: (5732 Views)
Objective (s): Currently there is no effective treatment and vaccine for COVID-19. However, several studies showed that BCG vaccine has long lasting positive non-specific effects on several infectious and autoimmune diseases via ‘trained immunity’ mechanisms. Along with these exceptional properties of this vaccine, few ecological studies showed controversial association between the national vaccination policies and morbidity and mortality rate of COVID-19.
Methods: This Article, reviewed the immunological mechanisms that explain the enhanced immunity by BCG vaccine against COVID-19. Also the conducted ecological studies and the clinical trials that are being conducted by few countries were reviewed.
Results: Considering Iran’s national BCG vaccination program and the low evidence level of ecological studies, we suggest to Iranian universities of medical sciences to conduct low-cost but better epidemiological studies with short duration, using tuberculin test. These studies including case-control, historical cohort and survival analysis studies, which will assess the association between immunity against tuberculosis and COVID-19 and its prognosis. The results of these studies may guide researchers about the necessity of conducting clinical trials among high risk groups like hospital staffs.
Conclusion: Also as few studies have shown BCG vaccine has therapeutic effects on patients with type 1 diabetes and multiple sclerosis, conducting clinical trials among Iranian patients can measure not only the preventive effect of BCG vaccine against COVID-19 but also the therapeutic effect on these two chronic diseases also.
Methods: This Article, reviewed the immunological mechanisms that explain the enhanced immunity by BCG vaccine against COVID-19. Also the conducted ecological studies and the clinical trials that are being conducted by few countries were reviewed.
Results: Considering Iran’s national BCG vaccination program and the low evidence level of ecological studies, we suggest to Iranian universities of medical sciences to conduct low-cost but better epidemiological studies with short duration, using tuberculin test. These studies including case-control, historical cohort and survival analysis studies, which will assess the association between immunity against tuberculosis and COVID-19 and its prognosis. The results of these studies may guide researchers about the necessity of conducting clinical trials among high risk groups like hospital staffs.
Conclusion: Also as few studies have shown BCG vaccine has therapeutic effects on patients with type 1 diabetes and multiple sclerosis, conducting clinical trials among Iranian patients can measure not only the preventive effect of BCG vaccine against COVID-19 but also the therapeutic effect on these two chronic diseases also.
type of study: Systematic Reviw |
Received: 2020/04/25 | Accepted: 2020/04/29 | ePublished ahead of print: 2020/05/3 | Published: 2020/05/5
Received: 2020/04/25 | Accepted: 2020/04/29 | ePublished ahead of print: 2020/05/3 | Published: 2020/05/5
References
1. Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines 2020; 8: 153-61 [DOI:10.3390/vaccines8020153]
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 395: 1054-62 [DOI:10.1016/S0140-6736(20)30566-3]
3. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clinical Infectious Diseases 2005; 41: S504-12 [DOI:10.1086/432007]
4. Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, Tang DC, et al. T cell responses to whole SARS coronavirus in humans. The Journal of Immunology 2008;18: 5490-500 [DOI:10.4049/jimmunol.181.8.5490]
5. O'Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK. Role of IL-12 in the induction and potentiation of IFN-γ in response to bacillus Calmette-Guérin. The Journal of Immunology 1999; 163: 4246-52
6. Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining trained immunity and its role in health and disease. Nature Reviews Immunology 2020;2: 1-4 [DOI:10.1038/s41577-020-0285-6]
7. Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LA, Jacobs C, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. Journal of Innate Immunity 2014; 6: 152-8 [DOI:10.1159/000355628]
8. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, et al. Bladder cancer. The Lancet 2016; 388: 2796-810 [DOI:10.1016/S0140-6736(16)30512-8]
9. Morton DL, Mozzillo N, Thompson JF, Kelley MC, Faries M, Wagner J, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. Journal of Clinical Oncology 2007; 25: 8508-8508 [DOI:10.1200/jco.2007.25.18_suppl.8508]
10. Von Hertzen LC, Haahtela T. Could the risk of asthma and atopy be reduced by a vaccine that induces a strong T-helper type 1 response?. American Journal of Respiratory Cell and Molecular Biology 2000; 22: 139-42 [DOI:10.1165/ajrcmb.22.2.3753]
11. El-Zein M, Parent ME, Benedetti A, Rousseau MC. Does BCG vaccination protect against the development of childhood asthma? A systematic review and meta-analysis of epidemiological studies. International Journal of Epidemiology 2010; 39: 469-86 [DOI:10.1093/ije/dyp307]
12. Roth A, Gustafson P, Nhaga A, Djana Q, Poulsen A, Garly ML, et al. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. International Journal of Epidemiology 2005; 34: 540-7 [DOI:10.1093/ije/dyh392]
13. Wardhana DE, Sultana A, Mandang VV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Medica Indonesia 2011; 43: 185-90
14. Wang Z, Hong J, Sun W, Xu G, Li N, Chen X, et al. Role of IFN-γ in induction of Foxp3 and conversion of CD4+ CD25-T cells to CD4+ Tregs. The Journal of Clinical Investigation 2006; 116: 2434-41 [DOI:10.1172/JCI25826]
15. Kühtreiber WM, Tran L, Kim T, Dybala M, Nguyen B, Plager S, et al. Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. Nature Partner Journal Vaccines 2018; 3:1-4 [DOI:10.1038/s41541-018-0062-8]
16. Ristori G, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, et al. Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis. Neurology 1999; 53: 1588-93 [DOI:10.1212/WNL.53.7.1588]
17. https://www.health.harvard.edu/diseases-and-conditions/tuberculosis-vaccine-shows-promise-in-controlling-blood-sugar
18. Devi D, Saniya G. Connecting BCG Vaccination and COVID-19: Additional Data. medRxiv 2020; Preprint available at: [DOI:10.1101/2020.04.07.20053272]
19. https://www.irishtimes.com/news/health/coronavirus-more-striking-evidence-bcg-vaccine-might-protect-against-covid-19-1.4222110
20. Klinger D, Blass I, Rappoport N, Linial M. Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis. medRxiv 2020; Preprint available at: [DOI:10.1101/2020.04.23.20077123]
21. Li Y, Zhao S, Zhuang Z, Cao P, Yang L, He D. The Correlation between BCG Immunization Coverage and the Severity of COVID-19. SSRN 2020; Preprint available at: https://ssrn.com/abstract=3568954 [DOI:10.2139/ssrn.3568954]
22. Hensel J, McGrail DJ, McAndrews KM, Dowlatshahi D, LeBleu VS, Kalluri R. Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing. medRxiv 2020; Preprint available at: [DOI:10.1101/2020.04.08.20056051]
23. Asahara M. The effect of BCG vaccination on COVID-19 examined by a statistical approach: no positive results from the Diamond Princess and cross-national differences previously reported by world-wide comparisons are flawed in several ways. medRxiv 2020; Preprint available at: [DOI:10.1101/2020.04.17.20068601]
24. Curtis N. BCG Vaccination to protect healthcare workers against COVID-19 (BRACE). Clinicaltrials 2020; Available at: https://clinicaltrials.gov/ct2/show/NCT04327206?term=BCG&draw=2&rank=3
25. Bonten MJM, Utrecht UMC. Reducing health care workers absenteeism in Covid19 pandemic through BCG Vaccine (BCG-CORONA). Clinicaltrials 2020; Available at: https://clinicaltrials.gov/ct2/show/NCT04328441?term=BCG&draw=2&rank=7
26. https://clinicaltrials.gov/ct2/results?cond=COVID&term=bcg&cntry=&state=&city=&dist=&Search=Search
27. https://theprint.in/india/bcg-vaccine-trials-to-begin-in-2-weeks-on-high-risk-covid-19-groups-in-maharashtra/405189/
28. World Health Organization. Bacille Calmette-Guérin (BCG) vaccination and COVID-19: scientific brief, 12 April 2020. World Health Organization 2020; Avalable at: https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19
29. http://www.bcgatlas.org/index.php
30. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Medicine 2011;8: e1001012. [DOI:10.1371/journal.pmed.1001012]
31. WHO immunization contraindication policy at: https://www.who.int/immunization/policy/contraindications.pdf
32. Redelman-Sidi, G. Could BCG be used to protect against COVID-19?. Nature Reviews Urology 2020; Avalable at: [DOI:10.1038/s41585-020-0325-9]
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |